Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.

PubWeight™: 0.98‹?› | Rank: Top 15%

🔗 View Article (PMC 3543488)

Published in Dig Dis Sci on August 24, 2012

Authors

Feng Hong1, Hsini Chou, Maria Isabel Fiel, Scott L Friedman

Author Affiliations

1: Division of Liver Diseases, Mount Sinai School of Medicine, Box 1123, 1425 Madison Ave., Room 1170C, New York, NY 10029, USA.

Articles citing this

CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut (2014) 1.91

Pathobiology of liver fibrosis: a translational success story. Gut (2015) 1.72

Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci (2014) 0.95

Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89

New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials. Front Pharmacol (2016) 0.81

The role of chemokines in hepatitis C virus-mediated liver disease. Int J Mol Sci (2014) 0.81

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. Braz J Med Biol Res (2015) 0.80

An algorithm that predicts the viability and the yield of human hepatocytes isolated from remnant liver pieces obtained from liver resections. PLoS One (2014) 0.80

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc Natl Acad Sci U S A (2015) 0.79

Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon Gamma. Front Med (Lausanne) (2015) 0.78

MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis (2017) 0.77

Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. Front Pharmacol (2016) 0.76

Levistilide A inhibits angiogenesis in liver fibrosis via vascular endothelial growth factor signaling pathway. Exp Biol Med (Maywood) (2017) 0.75

The influence of astragalus polysaccharide and β-elemene on LX-2 cell growth, apoptosis and activation. BMC Gastroenterol (2014) 0.75

Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma? World J Gastroenterol (2013) 0.75

Articles cited by this

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

TGF-beta and epithelial-to-mesenchymal transitions. Oncogene (2005) 10.02

Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem (2000) 9.07

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut (2005) 5.39

Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest (1998) 5.27

Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82

Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology (1992) 2.40

Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis (2001) 2.35

Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology (2002) 2.06

Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest (1994) 1.91

Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology (1999) 1.62

Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol Aspects Med (2007) 1.59

New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol (2010) 1.38

Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol (2007) 1.26

Thioacetamide-induced cirrhosis-like liver lesions in rats--usefulness and reliability of this animal model. Exp Pathol (1988) 1.25

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology (2011) 1.17

Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. J Hepatol (2002) 1.17

Articles by these authors

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82

Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54

Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci (2002) 2.49

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21

Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13

Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11

Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology (2008) 2.04

A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98

Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology (2004) 1.94

Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology (2012) 1.91

Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88

Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol (2006) 1.86

Scraping fibrosis: expressway to the core of fibrosis. Nat Med (2011) 1.82

Functions of autophagy in normal and diseased liver. Autophagy (2013) 1.81

Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol (2006) 1.79

Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology (2013) 1.78

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2002) 1.76

Hepatic stellate cells and liver fibrosis. Compr Physiol (2013) 1.75

Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72

Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology (2006) 1.71

Hepatic fibrosis. Curr Opin Gastroenterol (2009) 1.67

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res (2005) 1.65

Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice. Hepatology (2014) 1.62

The movement of aquatic mercury through terrestrial food webs. Science (2008) 1.61

Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61

Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology (2004) 1.59

Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res (2004) 1.57

Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52

Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res (2006) 1.51

Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem (2001) 1.51

Hepatic fibrosis--role of hepatic stellate cell activation. MedGenMed (2002) 1.51

Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology (2003) 1.48

Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47

Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem (2005) 1.46

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44

Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem (2002) 1.43

Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology (2012) 1.40

Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology (2002) 1.40

Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood (2005) 1.39

Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem (2002) 1.38

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest (2008) 1.36

Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34

Lhx2-/- mice develop liver fibrosis. Proc Natl Acad Sci U S A (2004) 1.33

Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther (2007) 1.33

Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut (2006) 1.31

Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology (2008) 1.31

BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol (2005) 1.28

Hepatic fibrogenesis. Semin Liver Dis (2007) 1.27

A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology (2013) 1.27

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26

Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol (2013) 1.25

Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology (2009) 1.24

Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology (2012) 1.24

Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology (2010) 1.22

Stellate cells: a moving target in hepatic fibrogenesis. Hepatology (2004) 1.22

Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol (2005) 1.21

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21

Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Res (2005) 1.20

Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) (2013) 1.19

The RING finger protein, RNF8, interacts with retinoid X receptor alpha and enhances its transcription-stimulating activity. J Biol Chem (2004) 1.18

Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology (2010) 1.18

Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer (2007) 1.17

Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol (2008) 1.17

Retinoids in cancer chemoprevention. Curr Cancer Drug Targets (2004) 1.16

Molecular basis of hepatic fibrosis. Expert Rev Mol Med (2003) 1.14

KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst (2010) 1.14

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology (2015) 1.14

The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood (2009) 1.13

Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol (2011) 1.13

Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. J Hepatol (2013) 1.12

Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicol Sci (2005) 1.09

Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair (2010) 1.09

The role of chemokines in acute liver injury. Front Physiol (2012) 1.09

Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP). J Cell Physiol (2010) 1.07

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One (2013) 1.04

T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03

Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology (2004) 1.03

Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol (2009) 1.02

Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis (2003) 1.02

Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene (2004) 1.02

Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. Am J Physiol Gastrointest Liver Physiol (2013) 1.01

Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology (2012) 1.01

Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. J Immunotoxicol (2009) 1.01

CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology (2012) 1.01